Benzyl-α-GalNAc

Benzyl-α-GalNAc is a potent O-glycosylation inhibitor. Benzyl-α-GalNAc effectively inhibits the proliferation and activation of LX-2 cells and suppresses the expression of collagen I/III, which has good potential for investigation in liver fibrosis. Benzyl-α-GalNAc also significantly enhances the anti-tumour activity of 5-Fluorouracil (HY-90006) (e.g. pancreatic cancer) by inhibiting O-glycosylation[1][2][3].

Product Specifications

CAS Number

[3554-93-6]

UNSPSC

12352005

Target

Glycosyltransferase

Type

Reference compound

Related Pathways

Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/o-glycosylation-in-1.html

Concentration

10mM

Purity

99.93

Solubility

DMSO : ≥ 100 mg/mL|H2O : 7 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O[C@@H]([C@H]([C@@H](CO)O1)O)[C@@H](NC(C)=O)[C@H]1OCC2=CC=CC=C2

Molecular Formula

C15H21NO6

Molecular Weight

311.33

References & Citations

[1]Kalra AV, et al. Mucin impedes cytotoxic effect of 5-FU against growth of human pancreatic cancer cells: overcoming cellular barriers for therapeutic gain. Br J Cancer. 2007 Oct 8;97 (7) :910-8. Epub 2007 Oct 2.|[2]Fan X, et al. Protein O glycosylation regulates activation of hepatic stellate cells. Inflammation. 2013 Dec;36 (6) :1248-52. https://pubmed.ncbi.nlm.nih.gov/23743764/|[3]Kalra AV, et al. Mucin overexpression limits the effectiveness of 5-FU by reducing intracellular drug uptake and antineoplastic drug effects in pancreatic tumours. Eur J Cancer. 2009 Jan;45 (1) :164-73.